Valganciclovir Drug Information
Generic name: VALGANCICLOVIR HYDROCHLORIDE
Uses of Valganciclovir
Pediatric Patients Prevention of CMV Disease: Valganciclovir is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk.
Dosage & Administration of Valganciclovir
General Dosing Information Valganciclovir for oral solution should be taken with food. Valganciclovir for oral solution (50 mg/mL) must be prepared by the pharmacist prior to dispensing to the patient.
Recommended Dosage in Pediatric Patients Prevention of CMV Disease in Pediatric Kidney Transplant Patients: For pediatric kidney transplant patients 4 months to 16 years of age, the recommended once daily mg dose (7 x BSA x CrCl) should start within 10 days of post-transplantation until 200 days post-transplantation. Prevention of CMV Disease in Pediatric Heart Transplant Patients: For pediatric heart transplant patients 1 month to 16 years of age, the recommended once daily mg dose (7 x BSA x CrCl) should start within 10 days of transplantation until 100 days post-transplantation. The recommended once daily dosage of valganciclovir for oral solution is based on body surface area (BSA) and creatinine clearance (CrCl) derived from a modified Schwartz formula, and is calculated using the equation below: Pediatric Dose (mg) = 7 x BSA x CrCl (calculated using a modified Schwartz formula).
The k values used in the modified Schwartz formula are based on pediatric patient age, as shown in Table 1. Table 1 k Values According to Monitor serum creatinine levels regularly and consider changes in height and body weight and adapt the dose as appropriate during prophylaxis period. All calculated doses should be rounded to the nearest 10 mg increment for the actual deliverable dose.
The oral dispenser is graduated in 0.2 mL increments. A 50 mg dose is equivalent to 1 mL. If the calculated dose exceeds 900 mg, a maximum dose of 900 mg should be administered.
Valganciclovir for oral solution is the preferred formulation since it provides the ability to administer a dose calculated according to the formula above. modified Schwartz formula
Preparation of Valganciclovir for Oral Solution
Wearing disposable gloves is recommended during reconstitution and when wiping the outer surface of the bottle/cap and the table after reconstitution. Prior to dispensing to the patient, valganciclovir for oral solution must be prepared by the pharmacist as follows: Measure 91 mL of purified water in a graduated cylinder. Shake the valganciclovir bottle to loosen the powder.
Remove the child resistant bottle cap and add approximately half the total amount of water for constitution to the bottle and shake the closed bottle well for about 1 minute. This prepared solution contains 50 mg of valganciclovir free base per 1 mL. Remove the child resistant bottle cap and push the bottle adapter into the neck of the bottle.
Close bottle with child resistant bottle cap tightly. This will assure the proper seating of the bottle adapter in the bottle and child resistant status of the cap. Store constituted oral solution under refrigeration at 2°C to 8°C (36°F to 46°F) for no longer than 49 days.
Do not freeze. Write the discard date of the constituted oral solution on the bottle label. The patient package insert, which includes the dosing instructions for patients, and 2 oral dispensers should be dispensed to the patient.
Handling and Disposal Caution should be exercised in the handling of valganciclovir for oral solution. Because valganciclovir is considered a potential teratogen and carcinogen in humans, caution should be observed in handling, the powder for oral solution, and the constituted oral solution. Avoid direct contact with the powder for oral solution, and the constituted oral solution with skin or mucous membranes.
If such contact occurs, wash thoroughly with soap and water, and rinse eyes thoroughly with plain water. Handle and dispose valganciclovir for oral solution according to guidelines for antineoplastic drugs because ganciclovir shares some of the properties of antitumor agents (i.e., carcinogenicity and mutagenicity). 2
| Pediatric Dosage ( 2.3 ) | |
| Prevention of CMV disease in kidney transplant patients 4 months to 16 years of age | Dose once a day within 10 days of transplantation until 200 days post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children) |
| Prevention of CMV disease in heart transplant patients 1 month to 16 years of age | Dose once a day within 10 days of transplantation until 100 days post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children) |
| k value | Pediatric Patient Age |
|---|---|
| 0.33 | Infants less than 1 year of age with low birth weight for gestational age |
| 0.45 | Infants less than 1 year of age with birth weight appropriate for gestational age |
| 0.45 | Children aged 1 to less than 2 years |
| 0.55 | Boys aged 2 to less than 13 years Girls aged 2 to less than 16 years |
| 0.7 | Boys aged 13 to 16 years |
| *The k values provided are based on the Jaffe method of measuring serum creatinine, and may require correction when enzymatic methods are used 1. | |
Side Effects of Valganciclovir
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice. Valganciclovir, a prodrug of ganciclovir, is rapidly converted to ganciclovir after oral administration. Adverse reactions known to be associated with ganciclovir usage can therefore be expected to occur with valganciclovir.
The incidence of adverse reactions was similar between the group who received valganciclovir tablets and the group who received intravenous ganciclovir. The frequencies of neutropenia (ANC less than 500/μL) were 11% for patients receiving valganciclovir tablets compared with 13% for patients receiving intravenous ganciclovir. Anemia (Hgb less than 8 g/dL) occurred in 8% of patients in each group.
Other laboratory abnormalities occurred with similar frequencies in the two groups. Adverse reactions and laboratory abnormalities are available for 370 patients who received maintenance therapy with valganciclovir tablets 900 mg once daily in two open-label clinical trials. Approximately 252 (68%) of these patients received valganciclovir tablets for more than nine months (maximum duration was 36 months).
Table 3 and Table 4 show pooled selected adverse reactions and abnormal laboratory values from these patients. Table 3 Pooled Selected Adverse Reactions Reported in greater than or equal to 5% of Patients who Received Maintenance Therapy for the Treatment of CMV Retinitis Prevention of CMV Disease in Solid Organ Transplant Patients: Table 5 shows selected adverse reactions regardless of severity with an incidence of greater than or equal to 5% from a clinical trial (up to 28 days after study treatment) where heart, kidney, kidney-pancreas and liver transplant patients received valganciclovir tablets (N=244) or oral ganciclovir (N=126) until Day 100 post-transplant. The majority of the adverse reactions were of mild or moderate intensity.
Table 5 Percentage of Selected Grades 1-4 Adverse Reactions Reported in greater than or equal to 5% of Adult Patients From a Study of Solid Organ Transplant Patients Table 6 shows selected adverse reactions regardless of severity with an incidence of greater than or equal to 5% from another clinical trial where kidney transplant patients received either valganciclovir once daily starting within 10 days post-transplant until Day 100 post-transplant followed by 100 days of placebo or valganciclovir once daily until Day 200 post-transplant. The overall safety profile of valganciclovir for oral solution did not change with the extension of prophylaxis until Day 200 post-transplant in high risk kidney transplant patients. Table 7 Selected Laboratory Abnormalities Reported in a Study of Adult Solid Organ Transplant Patients* *Laboratory abnormalities are those reported by investigators.
Table 8 Selected Laboratory Abnormalities Reported in a Study of Adult Kidney Transplant Patients* *Laboratory abnormalities are those reported by investigators. Other adverse drug reactions from valganciclovir in clinical trials in CMV retinitis and solid organ transplant patients Other adverse drug reactions with valganciclovir in clinical trials in either patients with CMV retinitis or solid organ transplant patients that occurred in at least 5% of patients are listed below. Eye disorders: retinal detachment, eye pain Gastrointestinal disorders: dyspepsia, constipation, abdominal distention, mouth ulceration General disorders and administration site conditions: fatigue, pain, malaise, asthenia, chills, peripheral edema Hepatobiliary disorders: hepatic function abnormal Infections and infestations: candida infections including oral candidiasis, upper respiratory tract infection, influenza, urinary tract infection, pharyngitis/nasopharyngitis, postoperative wound infection Injury, poisoning, and procedural complications: postoperative complications, wound secretion Metabolic and nutrition disorders: decreased appetite, hyperkalemia, hypophosphatemia, weight decreased Musculoskeletal and connective tissue disorders: back pain, myalgia, arthralgia, muscle spasms Nervous system disorders: insomnia, neuropathy peripheral, dizziness Psychiatric disorders: depression, anxiety Renal and urinary disorders: renal impairment, creatinine clearance renal decreased, blood creatinine increased, hematuria Respiratory, thoracic and mediastinal disorders: cough, dyspnea Skin and subcutaneous tissues disorders: dermatitis, night sweats, pruritus Vascular disorders: hypotension Other adverse reactions with valganciclovir in clinical trials in either patients with CMV retinitis or solid organ transplant patients that occurred in less than 5% of patients are listed below.
Blood and lymphatic disorders: febrile neutropenia, pancytopenia, bone marrow failure (including aplastic anemia) Cardiovascular disorders: arrhythmia Ear and labyrinth disorders: deafness Eye disorders: macular edema Gastrointestinal disorders: pancreatitis Hemorrhage: potentially life-threatening bleeding associated with thrombocytopenia Immune system disorders: hypersensitivity Infections and infestations: cellulitis, sepsis Injury, poisoning, and procedural complications: postoperative pain, wound dehiscence Investigations: aspartate aminotransferase increased, alanine aminotransferase increased Musculoskeletal and connective tissue disorders: limb pain Nervous system disorders: seizure, dysguesia (taste disturbance) Psychiatric disorders: confusional state, agitation, psychotic disorder, hallucinations Renal and urinary disorders: renal failure Adverse Reactions in Pediatric Patients: Valganciclovir for oral solution and tablets have been studied in 179 pediatric solid organ transplant patients who were at risk for developing CMV disease (aged 3 weeks to 16 years) and in 24 neonates with symptomatic congenital CMV disease (aged 8 to 34 days), with duration of ganciclovir exposure ranging from 2 to 200 days. Prevention of CMV Disease in Pediatric Solid Organ Transplant Patients: The most frequently reported adverse reactions (greater than 10% of patients), regardless of seriousness, in pediatric solid organ transplant patients taking valganciclovir for oral solution until Day 100 post-transplant were diarrhea, pyrexia, upper respiratory tract infection, vomiting, anemia, neutropenia, constipation and nausea. The most frequently reported adverse reactions (greater than 10% of patients) in pediatric kidney transplant patients treated with valganciclovir until Day 200 post-transplant were upper respiratory tract infection, urinary tract infection, diarrhea, leukopenia, neutropenia, headache, abdominal pain, tremor, pyrexia, anemia, blood creatinine increased, vomiting, and hematuria.
In general, the safety profile was similar in pediatric patients compared to that observed in adult patients. However, the rates of certain adverse reactions, and laboratory abnormalities, such as upper respiratory tract infection, pyrexia, nasopharyngitis, anemia, and abdominal pain were reported more frequently in pediatric patients than in adults. Neutropenia was reported at a higher incidence in the two pediatric studies as compared to adults, but there was no correlation between neutropenia and infections observed in the pediatric population.
The overall safety profile of valganciclovir was similar with the extension of prophylaxis until Day 200 post-transplant in high risk pediatric kidney transplant patients. There were no differences in the incidence of severe (Grade 4) anemia or thrombocytopenia in patients treated 100 or 200 days with valganciclovir.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of valganciclovir. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. As valganciclovir is rapidly and extensively converted to ganciclovir, any adverse reactions associated with ganciclovir might also occur with valganciclovir. - Anaphylactic reaction - Agranulocytosis - Granulocytopenia In general, the adverse reactions reported during the postmarketing use of valganciclovir were similar to those identified during the clinical trials.
To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
| Patients with CMV Retinitis | |
| Adverse Reactions according to Body System | Valganciclovir Tablets |
| (N=370) | |
| % | |
| Gastrointestinal system | |
| Diarrhea | 41 |
| Nausea | 30 |
| Vomiting | 21 |
| Abdominal pain | 15 |
| General disorders and administrative site conditions | |
| Pyrexia | 31 |
| Nervous system disorders | |
| Headache | 22 |
| Insomnia | 16 |
| Neuropathy peripheral | 9 |
| Paresthesia | 8 |
| Eye disorders | |
| Retinal detachment | 15 |
| Patients with CMV Retinitis | |
| Laboratory Abnormalities | Valganciclovir Tablets |
| (N=370) % | |
| Neutropenia: ANC/µL | |
| < 500 | 19 |
| 500 to < 750 | 17 |
| 750 to < 1000 | 17 |
| Anemia: Hemoglobin g/dL | |
| < 6.5 | 7 |
| 6.5 to < 8.0 | 13 |
| 8.0 to < 9.5 | 16 |
| Thrombocytopenia: Platelets/µL | |
| < 25000 | 4 |
| 25000 to < 50000 | 6 |
| 50000 to < 100000 | 22 |
| Serum Creatinine: mg/dL | |
| > 2.5 | 3 |
| > 1.5 to 2.5 | 12 |
| Adverse Reactions | Valganciclovir Tablets (N=244) % | Oral Ganciclovir (N=126) % |
|---|---|---|
| Gastrointestinal disorders | ||
| Diarrhea | 30 | 29 |
| Nausea | 23 | 23 |
| Vomiting | 16 | 14 |
| Nervous system disorders | ||
| Tremors | 28 | 25 |
| Headache | 22 | 27 |
| Insomnia | 20 | 16 |
| General disorders and administration site conditions | ||
| Pyrexia | 13 | 14 |
| Adverse Reactions | Valganciclovir Tablets Day 100 Post-transplant (N=164) % | Valganciclovir Tablets Day 200 Post- transplant (N=156) % |
|---|---|---|
| Gastrointestinal disorders | ||
| Diarrhea | 26 | 31 |
| Nausea | 11 | 11 |
| Vomiting | 3 | 6 |
| Nervous system disorders | ||
| Tremors | 12 | 17 |
| Headache | 10 | 6 |
| Insomnia | 7 | 6 |
| General disorders and administration site conditions | ||
| Pyrexia | 12 | 9 |
| Laboratory Abnormalities | Valganciclovir Tablets (N=244) % | Ganciclovir Capsules (N=126) % |
|---|---|---|
| Neutropenia: ANC/µL | ||
| < 500 | 5 | 3 |
| 500 to < 750 | 3 | 2 |
| 750 to < 1000 | 5 | 2 |
| Anemia: Hemoglobin g/dL | ||
| < 6.5 | 1 | 2 |
| 6.5 to < 8.0 | 5 | 7 |
| 8.0 to < 9.5 | 31 | 25 |
| Thrombocytopenia: Platelets/µL | ||
| < 25000 | 0 | 2 |
| 25000 to < 50000 | 1 | 3 |
| 50000 to < 100000 | 18 | 21 |
| Serum Creatinine: mg/dL | ||
| > 2.5 | 14 | 21 |
| > 1.5 to 2.5 | 45 | 47 |
| Laboratory Abnormalities | Valganciclovir Tablets Day 100 Post-transplant (N=164) % | Valganciclovir Tablets Day 200 Post-transplant (N=156) % |
|---|---|---|
| Neutropenia: ANC/µL | ||
| < 500 | 9 | 10 |
| 500 to < 750 | 6 | 6 |
| 750 to < 1000 | 7 | 5 |
| Anemia: Hemoglobin g/dL | ||
| < 6.5 | 0 | 1 |
| 6.5 to < 8.0 | 5 | 1 |
| 8.0 to < 9.5 | 17 | 15 |
| Thrombocytopenia: Platelets/µL | ||
| < 25000 | 0 | 0 |
| 25000 to < 50000 | 1 | 0 |
| 50000 to < 100000 | 7 | 3 |
| Serum Creatinine: mg/dL | ||
| > 2.5 | 17 | 14 |
| > 1.5 to 2.5 | 50 | 48 |
Warnings & Cautions for Valganciclovir
Hematologic Toxicity
Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with valganciclovir or ganciclovir. Valganciclovir for oral solution should be avoided if the absolute neutrophil count is less than 500 cells/μL, the platelet count is less than 25,000/μL, or the hemoglobin is less than 8 g/dL. Valganciclovir should also be used with caution in patients with pre-existing cytopenias and in patients receiving myelosuppressive drugs or irradiation.
Cytopenia may occur at any time during treatment and may worsen with continued dosing. Cell counts usually begin to recover within 3 to 7 days after discontinuing drug. In patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, treatment with hematopoietic growth factors may be considered.
Due to the frequency of neutropenia, anemia, and thrombocytopenia in patients receiving valganciclovir, complete blood counts with differential and platelet counts should be performed frequently, especially in infants, in patients with renal impairment, and in patients in whom ganciclovir or other nucleoside analogues have previously resulted in leukopenia, or in whom neutrophil counts are less than 1000 cells/μL at the beginning of treatment. Increased monitoring for cytopenias may be warranted if therapy with oral ganciclovir is changed to valganciclovir, because of increased plasma concentrations of ganciclovir after valganciclovir administration.
Acute Renal Failure
Acute renal failure may occur in: Elderly patients with or without reduced renal function. Caution should be exercised when administering valganciclovir to geriatric patients, and dosage reduction is recommended for those with impaired renal function. Patients receiving potential nephrotoxic drugs.
Caution should be exercised when administering valganciclovir to patients receiving potential nephrotoxic drugs. Patients without adequate hydration. Adequate hydration should be maintained for all patients.
Impairment of Fertility Based on animal data and limited human data, valganciclovir at the recommended human doses may cause temporary or permanent inhibition of spermatogenesis in males, and may cause suppression of fertility in females. Advise patients that fertility may be impaired with use of valganciclovir.
Fetal Toxicity Ganciclovir may cause fetal toxicity when administered to pregnant women based on findings in animal studies. When given to pregnant rabbits at dosages resulting in 2 times the human exposure (based on AUC), ganciclovir caused malformations in multiple organs of the fetuses. Maternal and fetal toxicity were also observed in pregnant mice and rabbits.
Therefore, valganciclovir has the potential to cause birth defects. Pregnancy should be avoided in female patients taking valganciclovir and in females with male partners taking valganciclovir. Females of reproductive potential should be advised to use effective contraception during treatment and for at least 30 days following treatment with valganciclovir because of the potential risk to the fetus.
Similarly, males should be advised to use condoms during and for at least 90 days following treatment with valganciclovir.
Mutagenesis and Carcinogenesis
Animal data indicate that ganciclovir is mutagenic and carcinogenic. Valganciclovir should therefore be considered a potential carcinogen in humans.
Drug Interactions with Valganciclovir
In vivo drug-drug interaction studies were not conducted with valganciclovir. However, because valganciclovir is rapidly and extensively converted to ganciclovir, drug-drug interactions associated with ganciclovir will be expected for valganciclovir. Drug-drug interaction studies with ganciclovir were conducted in patients with normal renal function.
Following concomitant administration of valganciclovir and other renally excreted drugs, patients with impaired renal function may have increased concentrations of ganciclovir and the coadministered drug. Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug. Established and other potentially significant drug interactions conducted with ganciclovir are listed in Table 9.
Table 9 Established and Other Potentially Significant Drug Interactions with Ganciclovir Monitor renal function when valganciclovir is coadministered with cyclosporine or amphotericin B because of potential increase in serum creatinine.: Seizures were reported in patients receiving ganciclovir and imipenem-cilastatin. Concomitant use is not recommended unless the potential benefits outweigh the risks. Cyclosporine or amphotericin B: When coadministered with valganciclovir, the risk of nephrotoxicity may be increased.
Monitor renal function. Mycophenolate mofetil (MMF): When coadministered with valganciclovir, the risk of hematological and renal toxicity may be increased. Monitor for ganciclovir and MMF toxicity.
Other drugs associated with myelosuppression or nephrotoxicity: Due to potential for increased toxicity, consider for concomitant use with valganciclovir only if the potential benefits are judged to outweigh the risks. Didanosine: Ganciclovir coadministered with didanosine may increase didanosine levels. Monitor for didanosine toxicity (e.g., pancreatitis).
Probenecid: May increase ganciclovir levels.
| Name of the Concomit a nt Drug | Change in the Concentration of Ganciclovir or Concomitant Drug | Clinical Comment |
|---|---|---|
| Imipenem-cilastatin | Unknown | Coadministration with imipenem cilastatin is not recommended because generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin. |
| Cyclosporine or amphotericin B | Unknown | Monitor renal function when valganciclovir is coadministered with cyclosporine or amphotericin B because of potential increase in serum creatinine [see Warnings and Precautions (5.2)]. |
| Mycophenolate mofetil (MMF) | ↔ Ganciclovir (in patients with normal renal function) ↔ MMF (in patients with normal renal function) | Based on increased risk, patients should be monitored for hematological and renal toxicity. |
| Other drugs associated with myelosuppression or nephrotoxicity (e.g., adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine, and zidovudine) | Unknown | Because of potential for higher toxicity, coadministration with valganciclovir should be considered only if the potential benefits are judged to outweigh the risks. |
| Didanosine | ↔ Ganciclovir ↑ Didanosine | Patients should be closely monitored for didanosine toxicity (e.g., pancreatitis) |
| Probenecid | ↑ Ganciclovir | Valganciclovir dose may need to be reduced. Monitor for evidence of ganciclovir toxicity. |
Pediatric Use of Valganciclovir
Pediatric Use Valganciclovir for oral solution and tablets are indicated for the prevention of CMV disease in pediatric kidney transplant patients 4 months to 16 years of age and in pediatric heart transplant patients 1 month to 16 years of age at risk for developing CMV disease. The use of valganciclovir hydrochloride for oral solution and tablets for the prevention of CMV disease in pediatric kidney transplant patients 4 months to 16 years of age is based on two single-arm, open-label, non-comparative studies in patients 4 months to 16 years of age. Study 1 was a safety and pharmacokinetic study in pediatric solid organ transplant patients (kidney, liver, heart, and kidney/pancreas).
Valganciclovir was administered once daily within 10 days of transplantation for a maximum of 100 days post-transplantation. The results of these studies were supported by previous demonstration of efficacy in adult patients. The use of valganciclovir for oral solution and tablets for the prevention of CMV disease in pediatric heart transplant patients 1 month to 16 years of age is based on two studies (Study 1 described above and Study 3) and was supported by previous demonstration of efficacy in adult patients.
Study 3 was a pharmacokinetic and safety study of valganciclovir for oral solution in pediatric heart transplant patients less than 4 months of age who received a single dose of valganciclovir for oral solution on each of two consecutive days. A physiologically based pharmacokinetic (PBPK) model was developed based on the available pharmacokinetic data from pediatric and adult patients to support dosing in heart transplant patients less than 1 month of age. However, due to uncertainty in model predictions for neonates, valganciclovir for oral solution is not indicated for prophylaxis in this age group.
The safety and efficacy of valganciclovir for oral solution and tablets have not been established in children for prevention of CMV disease in pediatric liver transplant patients, in kidney transplant patients less than 4 months of age, in heart transplant patients less than 1 month of age, in pediatric AIDS patients with CMV retinitis, and in infants with congenital CMV infection. A pharmacokinetic and pharmacodynamic evaluation of valganciclovir for oral solution was performed in 24 neonates with congenital CMV infection involving the central nervous system. All patients were treated for 6 weeks with a combination of intravenous ganciclovir 6 mg per kg twice daily or valganciclovir for oral solution at doses ranging from 14 mg per kg to 20 mg per kg twice daily.
The pharmacokinetic results showed that in infants greater than 7 days to 3 months of age, a dose of 16 mg per kg twice daily of valganciclovir for oral solution provided ganciclovir systemic exposures (median AUC 0-12h = 23.6 mcg ∙ h/mL; n = 6) comparable to those obtained in infants up to 3 months of age from a 6 mg per kg dose of intravenous ganciclovir twice daily (AUC 0-12h = 25.3 mcg ∙ h/mL; n = 18) or to the ganciclovir systemic exposures obtained in adults from a 900 mg dose of valganciclovir tablets twice daily. However, the efficacy and safety of intravenous ganciclovir and of valganciclovir for oral solution have not been established for the treatment of congenital CMV infection in infants and no similar disease occurs in adults; therefore, efficacy cannot be extrapolated from intravenous ganciclovir use in adults.
Contraindications for Valganciclovir
Valganciclovir for oral solution is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation. Hypersensitivity to valganciclovir or ganciclovir.
Overdosage Information for Valganciclovir
- Experience with Valganciclovir Tablets: An overdose of valganciclovir could possibly result in increased renal toxicity. Because ganciclovir is dialyzable, dialysis may be useful in reducing serum concentrations in patients who have received an overdose of valganciclovir. Adequate hydration should be maintained. The use of hematopoietic growth factors should be considered. Reports of adverse reactions after overdoses with valganciclovir, some with fatal outcomes, have been received from clinical trials and during postmarketing experience. The majority of patients experienced one or more of the following adverse events: Hematological toxicity: myelosuppression including pancytopenia, bone marrow failure, leukopenia, neutropenia, granulocytopenia Hepatotoxicity: hepatitis, liver function disorder Renal toxicity: worsening of hematuria in a patient with pre-existing renal impairment, acute kidney injury, elevated creatinine Gastrointestinal toxicity: abdominal pain, diarrhea, vomiting Neurotoxicity: generalized tremor, seizure
Clinical Studies of Valganciclovir
A determination of CMV retinitis progression by the masked review of retinal photographs taken at baseline and Week 4 was the primary outcome measurement of the 3-week induction therapy. Table 19 provides the outcomes at 4 weeks. Table 19 Week 4 Masked Review of Retinal Photographs in CMV Retinitis Study 6 5 Maintenance Therapy of CMV Retinitis: No comparative clinical data are available on the efficacy of valganciclovir tablets for the maintenance therapy of CMV retinitis because all patients in the CMV retinitis study received open-label valganciclovir tablets after Week 4.
However, the AUC for ganciclovir is similar following administration of 900 mg valganciclovir tablets once daily and 5 mg per kg intravenous ganciclovir once daily. Although the ganciclovir C max is lower following valganciclovir tablets administration compared to intravenous ganciclovir, it is higher than the C max obtained following oral ganciclovir administration. Therefore, use of valganciclovir tablets as maintenance therapy is supported by a plasma concentration-time profile similar to that of two approved products for maintenance therapy of CMV retinitis.
Prevention of CMV Disease in Heart, Kidney, Kidney-Pancreas, or Liver Transplantation: A double blind, double-dummy active comparator study was conducted in 372 heart, liver, kidney, or kidney-pancreas transplant patients at high risk for CMV disease (D+/R-). The proportion of patients who developed CMV disease, including CMV syndrome and/or tissue-invasive disease during the first 6 months post-transplant was similar between the valganciclovir tablets arm (12.1%, N=239) and the oral ganciclovir arm (15.2%, N=125). However, in liver transplant patients, the incidence of tissue-invasive CMV disease was significantly higher in the valganciclovir group compared with the ganciclovir group.
These results are summarized in Table 20. Table 20 Percentage of Patients with CMV Disease, Tissue-Invasive CMV Disease or CMV Syndrome by Organ Type: Endpoint Committee, 6 Month ITT Population = valganciclovir 1 Number of patients with CMV disease = Number of patients with tissue-invasive CMV disease or CMV syndrome 2 CMV syndrome was defined as evidence of CMV viremia accompanied with fever greater than or equal to 38°C on two or more occasions separated by at least 24 hours within a 7-day period and one or more of the following: malaise, leukopenia, atypical lymphocytosis, thrombocytopenia, and elevation of hepatic transaminases Prevention of CMV Disease in Kidney Transplantation: A double-blind, placebo-controlled study was conducted in 326 kidney transplant patients at high risk for CMV disease (D+/R-) to assess the efficacy and safety of extending valganciclovir CMV prophylaxis from 100 to 200 days post-transplant. Extending CMV prophylaxis with valganciclovir until Day 200 post-transplant demonstrated superiority in preventing CMV disease within the first 12 months post-transplant in high risk kidney transplant patients compared to the 100 day dosing regimen (primary endpoint).
These results are summarized in Table 21. Table 21 Percentage of Kidney Transplant Patients with CMV Disease, Tissue-Invasive CMV Disease or CMV Syndrome, 12 Month ITT Population = valganciclovir. 1 Number of patients with CMV disease = Number of patients with tissue-invasive CMV disease or CMV syndrome 2 CMV syndrome was defined as evidence of CMV viremia accompanied with at least one of the following: fever (greater than or equal to 38°C), severe malaise, leukopenia, atypical lymphocytosis, thrombocytopenia, and elevation of hepatic transaminases 3 Two patients in the 100 day group had both tissue-invasive CMV disease and CMV syndrome; however, these patients are counted as having only tissue-invasive CMV disease. Patients received valganciclovir once daily within 10 days after transplant until a maximum of 100 days post-transplant.
The daily doses of valganciclovir were calculated at each study visit based on body surface area and a modified creatinine clearance. The pharmacokinetics of ganciclovir were similar across organ transplant types and age ranges. The mean daily ganciclovir exposures in pediatric patients were somewhat increased relative to those observed in adult solid organ transplant patients receiving valganciclovir 900 mg once daily, but were within the range considered safe and effective in adults.
No case of CMV syndrome or tissue-invasive CMV disease was reported within the first six months post-transplantation. Prevention of CMV in Pediatric Kidney Transplantation: Fifty-seven children, 1 to 16 years of age, who had a renal transplant and were at risk for developing CMV disease, were enrolled in an open-label tolerability study of oral valganciclovir (valganciclovir for oral solution or tablets).
| Intravenous Ganciclovir | Valganciclovir Tablets | |
|---|---|---|
| Determination of CMV retinitis progression at Week 4 | N=80 | N=80 |
| Progressor | 7 | 7 |
| Non-progressor | 63 | 64 |
| Death | 2 | 1 |
| Discontinuations due to Adverse Events | 1 | 2 |
| Failed to return | 1 | 1 |
| CMV not confirmed at baseline or no interpretable baseline photos | 6 | 5 |
| CMV Disease 1 | Tissue-Invasive CMV Disease | CMV Syndrome 2 | ||||
|---|---|---|---|---|---|---|
| Organ | VGCV | GCV | VGCV | GCV | VGCV | GCV |
| (N=239) | (N=125) | (N=239) | (N=125) | (N=239) | (N=125) | |
| Liver | 19% | 12% | 14% | 3% | 5% | 8% |
| (n=177) | (22/118) | (7/59) | (16/118) | (2/59) | (6/118) | (5/59) |
| Kidney | 6% | 23% | 1% | 5% | 5% | 18% |
| (n=120) | (5/81) | (9/39) | (1/81) | (2/39) | (4/81) | (7/39) |
| Heart | 6% | 10% | 0% | 5% | 6% | 5% |
| (n=56) | (2/35) | (2/21) | (0/35) | (1/21) | (2/35) | (1/21) |
| Kidney/Pancreas | 0% | 17% | 0% | 17% | 0% | 0% |
| (n=11) | (0/5) | (1/6) | (0/5) | (1/6) | (0/5) | (0/6) |
| CMV Disease 1 | Tissue-Invasive CMV Disease | CMV Syndrome 2 | ||||
|---|---|---|---|---|---|---|
| 100 Days VGCV (N=163) | 200 Days VGCV (N=155) | 100 Days VGCV (N=163) | 200 Days VGCV (N=155) | 100 Days VGCV (N=163) | 200 Days VGCV (N=155) | |
| Cases | 36.8% (60/163) | 16.8% (26/155) | 1.8% (3/163) 3 | 0.6% (1/155) | 35. 0% (57/163) | 16.1% (25/155) |
Drug information sourced from the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before making any medication decisions.
Ready to save on Valganciclovir?
Compare prescription prices at over 70,000 pharmacies and start saving today—no enrollment required.
Compare Valganciclovir Prices